Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US
Supportive Care in Cancer,
Год журнала:
2024,
Номер
32(8)
Опубликована: Июль 9, 2024
Язык: Английский
Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(17), С. 9371 - 9371
Опубликована: Авг. 29, 2024
The
paradigm
“one
drug
fits
all”
or
dose
will
soon
be
challenged
by
pharmacogenetics
research
and
application.
Drug
response—efficacy
safety—depends
on
interindividual
variability.
current
clinical
practice
does
not
include
genetic
screening
as
a
routine
procedure
account
for
variation.
Patients
with
the
same
illness
receive
treatment,
yielding
different
responses.
Integrating
pharmacogenomics
in
therapy
would
provide
critical
information
about
how
patient
respond
to
certain
drug.
Worldwide,
great
efforts
are
being
made
achieve
personalized
therapy-based
approach.
Nevertheless,
global
harmonized
guideline
is
still
needed.
Plasma
membrane
proteins,
like
receptor
tyrosine
kinase
(RTK)
G
protein-coupled
receptors
(GPCRs),
ubiquitously
expressed,
involved
diverse
array
of
physiopathological
processes.
Over
30%
drugs
approved
FDA
target
GPCRs,
reflecting
importance
assessing
variability
among
individuals
who
treated
these
drugs.
Pharmacogenomics
transmembrane
protein
dynamic
field
profound
implications
precision
medicine.
Understanding
variations
provides
framework
optimizing
therapies,
minimizing
adverse
reactions,
advancing
healthcare.
Язык: Английский
Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs
British Journal of Clinical Pharmacology,
Год журнала:
2024,
Номер
90(7), С. 1699 - 1710
Опубликована: Апрель 14, 2024
Genetic
testing
can
be
used
to
improve
the
safety
and
effectiveness
of
commonly
prescribed
medicines-a
concept
known
as
pharmacogenetics.
This
study
aimed
quantify
members
UK
public's
preferences
for
a
pharmacogenetic
service
delivered
in
primary
care
National
Health
Service.
Язык: Английский
Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Май 14, 2024
Abstract
Purpose
Patients
with
dihydropyrimidine
dehydrogenase
(DPD)
deficiency
are
at
high
risk
for
severe
and
fatal
toxicity
from
fluoropyrimidine
(FP)
chemotherapy.
Pre-treatment
DPYD
testing
is
standard
of
care
in
many
countries,
but
not
the
United
States
(US).
This
survey
assessed
pre-treatment
approaches
US
to
identify
best
practices
broader
adoption.
Methods
From
August
October
2023,
a
22-item
Qualtrics
XM
was
sent
institutions
clinicians
known
conduct
broadly
distributed
through
relevant
organizations
social
networks.
Responses
were
analyzed
using
descriptive
analysis.
Results
24
unique
sites
that
have
implemented
or
detailed
implementation
plan
place
analyzed.
Only
33%
ordered
all
FP-treated
patients;
remaining
sites,
patients
tested
depending
on
disease
characteristics
clinician
preference.
Almost
50%
depend
individual
remember
order
without
assistance
electronic
alerts
workflow
reminders.
most
often
conducted
by
commercial
laboratories
least
4
5
variants
considered
clinically
actionable.
Approximately
90%
reported
receiving
results
within
10
days
ordering.
Conclusion
Implementing
into
routine
clinical
practice
feasible
requires
coordinated
effort
among
healthcare
team.
These
will
be
used
develop
adoption
prevent
cancer
FP
Язык: Английский
The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 14, 2024
Abstract
Pharmacogenomic
(PGx)
considerations
are
increasingly
influencing
health
system
formularies,
prompting
Pharmacy
and
Therapeutics
(P&T)
committees
to
integrate
genetic
insights
into
their
decision‐making
processes.
This
can
be
the
case
in
several
clinical
scenarios,
including
(1)
Prioritizing
use
of
lower‐cost
drugs,
where
PGx
testing
is
applied
guide
medications
when
appropriate,
(2)
Rescuing
that
effective
majority
individuals
but
were
removed
from
formulary
because
harm
a
subset
with
specific
phenotype,
(3)
Improving
medication
safety
by
utilizing
testing/results
initiation
reduced
drug
doses
or
alternative
therapy
patients
at‐risk
genotypes,
(4)
Restricting
high‐cost
drugs
most
likely
respond
based
on
genotype.
The
primary
objective
this
PRN
opinion
piece
describe
how
impacts
management,
challenges
opportunities
arise
precision
medicine
approaches
prescribing.
Язык: Английский